drugset / Trial / NCT07052214
PSMA PET Combined With MRI for the Detection of PCa
Phase 3
Recruiting
204 enrolled
Telix Pharmaceuticals (Innovations) Pty Limited
Telix Innovations S.A. · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).
Timeline
- Start
- 2025-08-18
- Primary completion
- 2026-06
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | — | Intravenous |